Review
Biochemistry & Molecular Biology
Roopak Murali, Vaishnavi Balasubramaniam, Satish Srinivas, Sandhya Sundaram, Ganesh Venkatraman, Sudha Warrier, Arun Dharmarajan, Rajesh Kumar Gandhirajan
Summary: Ovarian cancers are a type of tumor that originates from different cells of the ovary and account for around 4% of all cancers in women worldwide. There are more than 30 identified tumor types based on cellular origins, with epithelial ovarian cancer (EOC) being the most common and deadly type. EOC can be further categorized into different subtypes. The development of ovarian cancer has long been associated with endometriosis, a chronic inflammation leading to the accumulation of mutations. Recent studies have elucidated the role of somatic mutations and their impact on altered tumor metabolism. Several oncogenes and tumor suppressor genes have been implicated in ovarian cancer progression. This review highlights the genetic alterations and their impact on metabolic networks in ovarian cancer, providing insights into potential personalized therapies.
Review
Biochemistry & Molecular Biology
Irina Gilyazova, Kadriia Enikeeva, Guzel Rafikova, Evelina Kagirova, Yuliya Sharifyanova, Dilara Asadullina, Valentin Pavlov
Summary: Bladder cancer is a common malignant tumor of the urogenital system, with over 500,000 new cases worldwide annually. Current diagnosis methods include cystoscopy and urine cytology, but they have limitations in sensitivity and invasiveness. There is a need to develop more reliable markers and tests for early detection of the disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Valeria Pietropaolo, Carla Prezioso, Ugo Moens
Summary: Tumor viruses such as HTLV-1, HCV, MCPyV, HR-HPVs, EBV, KSHV, and HBV play a role in approximately 15% of all human cancers, using similar mechanisms to convey cancer hallmarks to infected cells. Perturbed gene expression and epigenetic processes, including DNA methylation and histone modification, are key mechanisms in virus-induced carcinogenesis. Increasing evidence shows that oncoviruses cause epigenetic modifications which are crucial in cancer development.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cell Biology
William Lee, Zishan Wang, Miriam Saffern, Tomi Jun, Kuan-lin Huang
Summary: Young adult tumors exhibit unique genomic characteristics with more driver mutations and copy-number alterations compared to later-onset tumors, despite lower overall mutation burden. Analysis of tumor immune microenvironments reveals elevated TGF-b response and decreased IFN-g response in young adult tumors, compared to later-onset tumors.
Article
Biochemistry & Molecular Biology
Urszula Oleksiewicz, Marta Machnik, Joanna Sobocinska, Sara Molenda, Anna Olechnowicz, Anna Florczak, Mikolaj Smolibowski, Mariusz Kaczmarek
Summary: The study reveals that ZNF714 is frequently overexpressed in multiple tumors, possibly due to regional amplification, promoter hypomethylation, and NFYB signaling. ZNF714 expression is correlated with tumor immunosuppressive features and positively associated with proliferation, migration, and invasion in vitro. It is suggested that ZNF714 may play a potential oncogenic role in cancer development by indirectly regulating the expression of several known TSGs through promoter methylation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Jeyshka M. Reyes-Gonzalez, Pablo E. Vivas-Mejia
Summary: Ovarian cancer is the deadliest gynecological malignancy with a 5-year survival rate of approximately 49%. Standard treatment involves cytoreductive surgery and platinum-based chemotherapy, but platinum resistance is a major challenge. Identifying effective biomarkers and therapeutic targets is crucial for guiding therapy and improving patient outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Carolin Salmon, Janina Levermann, Rui P. L. Neves, Sven-Thorsten Liffers, Jan Dominik Kuhlmann, Paul Buderath, Rainer Kimmig, Sabine Kasimir-Bauer
Summary: Analysis of single circulating tumor cells (sCTCs) in Ovarian Cancer (OC) may aid in studying genetic tumor evolution during treatment. A workflow for detection and genomic analysis of CTCs in OC patients has been presented, aiming to improve detection rate and provide insights into tumor evolution. Further studies and identification markers are being pursued to expand sCTC analysis for tumor evolution in OC patients.
Article
Immunology
Min Zhou, Bingshu Li, Jianfeng Liu, Li Hong
Summary: This study highlights the crucial role of pyroptosis-related genes in the tumor microenvironment, providing insights for developing immunotherapies and promoting individualized therapeutic strategies for patients with gynecological cancers.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Oncology
James McDonald, Noor Diab, Elisa Arthofer, Melissa Hadley, Tomas Kanholm, Uzma Rentia, Stephanie Gomez, Angela Yu, Erin E. Grundy, Olivia Cox, Michael J. Topper, Xiaoyun Xing, Pamela L. Strissel, Reiner Strick, Ting Wang, Stephen B. Baylin, Katherine B. Chiappinelli
Summary: The study shows that epigenetic therapies can enhance immune response and recruit immune cells to fight ovarian carcinoma by targeting the epigenome, with a role for p53 in this process. Different types of epigenetic therapy result in upregulation of different repetitive elements, and cell lines with TP53 mutations exhibit weaker response.
Review
Medicine, Research & Experimental
Nathalie D. Mckenzie, Sarfraz Ahmad, Ahmad Awada, Theresa M. Kuhn, Fernando O. Recio, Robert W. Holloway
Summary: The prognosis of high-grade serous ovarian cancer is influenced by the immune profile of the tumor microenvironment. Altering the gut microbiome and TME metabolism through dietary interventions may provide opportunities for immunomodulation.
Article
Biochemistry & Molecular Biology
Sadaf Harandi-Zadeh, Cayla Boycott, Megan Beetch, Tony Yang, Benjamin J. E. Martin, Kevin Ren, Anna Kwasniak, John H. Dupuis, Katarzyna Lubecka, Rickey Y. Yada, LeAnn J. Howe, Barbara Stefanska
Summary: Epigenetic aberrations are associated with sporadic breast cancer, and dietary polyphenols such as pterostilbene have been shown to regulate gene expression by altering epigenetic patterns. The study reveals an impact of pterostilbene on enhancer regions in breast cancer cells, affecting DNMT3B binding, H3K36me3 levels, enhancer hypermethylation, and gene expression downregulation. Additionally, the research highlights the involvement of oncogenic transcription factor OCT1 in mediating the effects of pterostilbene on enhancers and gene expression in breast cancer cells.
Article
Medicine, Research & Experimental
Onat Kadioglu, Mohamed E. M. Saeed, Nuha Mahmoud, Shaymaa Azawi, Kristin Mrasek, Thomas Liehr, Thomas Efferth
Summary: The study characterized U87.MG Delta EGFR glioblastoma cells with constitutively active EGFR and identified novel drug resistance mechanisms related to the expression of mutation-activated EGFR. The cells showed numerous chromosomal aberrations and gene overexpression, including well-known drug resistance genes and novel ones. These findings may have important implications for future treatment strategies.
Article
Immunology
Fangfang Xu, Tingwei Liu, Zhuonan Zhou, Chang Zou, Shaohua Xu
Summary: The study identified APOBEC3A as a protective factor and a promising prognostic biomarker for forecasting the survival and immunotherapy effect of OC patients, potentially accelerating the clinical application and improving immunotherapy effect.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Richard Heery, Martin H. Schaefer
Summary: While large-scale studies have identified hundreds of mutated driver genes in various cancer types, the contribution of epigenetic changes to cancer remains unclear. A novel method correcting for epigenetic covariates reveals a concise set of potential epigenetic driver events, indicating higher convergence on common tumor suppressor pathways and higher tolerance of other aberrations in prostate cancer.
NUCLEIC ACIDS RESEARCH
(2021)
Review
Oncology
Aisling Y. Coughlan, Giuseppe Testa
Summary: Ovarian cancer therapy has not seen significant advancements in the past 50 years, with surgery and chemotherapy remaining the main treatments. Alterations in epigenetic regulators are closely associated with ovarian cancer and may serve as therapeutic targets. New models and technologies allow for a better understanding of the epigenetic pathways in ovarian cancer.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Editorial Material
Oncology
Nita J. Maihle, Douglas A. Levine, Kiran Dhillon, Deborah Kay Armstrong
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2019)
Article
Biochemistry & Molecular Biology
Yongchao Dou, Emily A. Kawaler, Daniel Cui Zhou, Marina A. Gritsenko, Chen Huang, Lili Blumenberg, Alla Karpova, Vladislav A. Petyuk, Sara R. Savage, Shankha Satpathy, Wenke Liu, Yige Wu, Chia-Feng Tsai, Bo Wen, Zhi Li, Song Cao, Jamie Moon, Zhiao Shi, MacIntosh Cornwell, Matthew A. Wyczalkowski, Rosalie K. Chu, Suhas Vasaikar, Hua Zhou, Qingsong Gao, Ronald J. Moore, Kai Li, Sunantha Sethuraman, Matthew E. Monroe, Rui Zhao, David Heiman, Karsten Krug, Karl Clauser, Ramani Kothadia, Yosef Maruvka, Alexander R. Pico, Amanda E. Oliphant, Emily L. Hoskins, Samuel L. Pugh, Sean J. I. Beecroft, David W. Adams, Jonathan C. Jarman, Andy Kong, Hui-Yin Chang, Boris Reva, Yuxing Liao, Dmitry Rykunov, Antonio Colaprico, Xi Steven Chen, Andrzej Czekanski, Marcin Jedryka, Rafa Matkowski, Maciej Wiznerowicz, Tara Hiltke, Emily Boja, Christopher R. Kinsinger, Mehdi Mesri, Ana I. Robles, Henry Rodriguez, David Mutch, Katherine Fuh, Matthew J. Ellis, Deborah DeLair, Mathangi Thiagarajan, D. R. Mani, Gad Getz, Michael Noble, Alexey I. Nesvizhskii, Pei Wang, Matthew L. Anderson, Douglas A. Levine, Richard D. Smith, Samuel H. Payne, Kelly V. Ruggles, Karin D. Rodland, Li Ding, Bing Zhang, Tao Liu, David Fenyo
Article
Oncology
Melissa K. Frey, Sarah S. Lee, Deanna Gerber, Zachary P. Schwartz, Jessica Martineau, Kathleen Lutz, Erin Reese, Emily Dalton, Annie Olsen, Julia Girdler, Bhavana Pothuri, Leslie Boyd, John P. Curtin, Douglas A. Levine, Stephanie Blank
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Panagiotis A. Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N. Grisham, Paul J. Goodfellow, Elise C. Kohn, Douglas A. Levine, Joyce F. Liu, Karen H. Lu, Dorinda Sparacio, Christina M. Annunziata
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
J. Millstein, T. Budden, E. L. Goode, M. S. Anglesio, A. Talhouk, M. P. Intermaggio, H. S. Leong, S. Chen, W. Elatre, B. Gilks, T. Nazeran, M. Volchek, R. C. Bentley, C. Wang, D. S. Chiu, S. Kommoss, S. C. Y. Leung, J. Senz, A. Lum, V Chow, H. Sudderuddin, R. Mackenzie, J. George, S. Fereday, J. Hendley, N. Traficante, H. Steed, J. M. Koziak, M. Kobel, I. A. McNeish, T. Goranova, D. Ennis, G. Macintyre, D. Silva De Silva, T. Ramon y Cajal, J. Garcia-Donas, S. Hernando Polo, G. C. Rodriguez, K. L. Cushing-Haugen, H. R. Harris, C. S. Greene, R. A. Zelaya, S. Behrens, R. T. Fortner, P. Sinn, E. Herpel, J. Lester, J. Lubinski, O. Oszurek, A. Toloczko, C. Cybulski, J. Menkiszak, C. L. Pearce, M. C. Pike, C. Tseng, J. Alsop, V Rhenius, H. Song, M. Jimenez-Linan, A. M. Piskorz, A. Gentry-Maharaj, C. Karpinskyj, M. Widschwendter, N. Singh, C. J. Kennedy, R. Sharma, P. R. Harnett, B. Gao, S. E. Johnatty, R. Sayer, J. Boros, S. J. Winham, G. L. Keeney, S. H. Kaufmann, M. C. Larson, H. Luk, B. Y. Hernandez, P. J. Thompson, L. R. Wilkens, M. E. Carney, B. Trabert, J. Lissowska, L. Brinton, M. E. Sherman, C. Bodelon, S. Hinsley, L. A. Lewsley, R. Glasspool, S. N. Banerjee, E. A. Stronach, P. Haluska, I Ray-Coquard, S. Mahner, B. Winterhoff, D. Slamon, D. A. Levine, L. E. Kelemen, J. Benitez, J. Chang-Claude, J. Gronwald, A. H. Wu, U. Menon, M. T. Goodman, J. M. Schildkraut, N. Wentzensen, R. Brown, A. Berchuck, G. Chenevix-Trench, A. DeFazio, S. A. Gayther, M. J. Garcia, M. J. Henderson, M. A. Rossing, A. Beeghly-Fadiel, P. A. Fasching, S. Orsulic, B. Y. Karlan, G. E. Konecny, D. G. Huntsman, D. D. Bowtell, J. D. Brenton, J. A. Doherty, P. D. P. Pharoah, S. J. Ramus
ANNALS OF ONCOLOGY
(2020)
Review
Oncology
Marc Tischkowitz, Sidong Huang, Susana Banerjee, Jennifer Hague, William P. D. Hendricks, David G. Huntsman, Jessica D. Lang, Krystal A. Orlando, Amit M. Oza, Patricia Pautier, Isabelle Ray-Coquard, Jeffrey M. Trent, Michael Witcher, Leora Witkowski, W. Glenn McCluggage, Douglas A. Levine, William D. Foulkes, Bernard E. Weissman
CLINICAL CANCER RESEARCH
(2020)
Editorial Material
Multidisciplinary Sciences
Victoria L. Bae-Jump, Douglas A. Levine
Article
Genetics & Heredity
Honglin Song, Ed M. Dicks, Jonathan Tyrer, Maria Intermaggio, Georgia Chenevix-Trench, David D. Bowtell, Nadia Traficante, James Brenton, Teodora Goranova, Karen Hosking, Anna Piskorz, Elke van Oudenhove, Jen Doherty, Holly R. Harris, Mary Anne Rossing, Matthias Duerst, Thilo Dork, Natalia Bogdanova, Francesmary Modugno, Kirsten Moysich, Kunle Odunsi, Roberta Ness, Beth Y. Karlan, Jenny Lester, Allan Jensen, Susanne Kruger Kjaer, Estrid Hogdall, Ian G. Campbell, Conxi Lazaro, Miguel Angel Pujara, Julie Cunningham, Robert Vierkant, Stacey J. Winham, Michelle Hildebrandt, Chad Huff, Donghui Li, Xifeng Wu, Yao Yu, Jennifer B. Permuth, Douglas A. Levine, Joellen M. Schildkraut, Marjorie J. Riggan, Andrew Berchuck, Penelope M. Webb, Cezary Cybulski, Jacek Gronwald, Anna Jakubowska, Jan Lubinski, Jennifer Alsop, Patricia Harrington, Isaac Chan, Usha Menon, Celeste L. Pearce, Anna H. Wu, Anna de Fazio, Catherine J. Kennedy, Ellen Goode, Susan Ramus, Simon Gayther, Paul Pharoah
Summary: This study aimed to investigate the contribution of rare deleterious germline variants in candidate genes to ovarian cancer susceptibility. The findings suggest a potential association between PALB2 mutations and increased risk of high-grade serous ovarian cancer, with further research needed to confirm the significance of other genes.
JOURNAL OF MEDICAL GENETICS
(2021)
Article
Oncology
Alexander Shushkevich, Premal H. Thaker, Ramey D. Littell, Naishadh A. Shah, Sarah Chiang, Katherine Thornton, Martee L. Hensley, Brian M. Slomovitz, Kevin M. Holcomb, Mario M. Leitao, Michael D. Toboni, Matthew A. Powell, Douglas A. Levine, Sean C. Dowdy, Ann Klopp, Jubilee Brown
GYNECOLOGIC ONCOLOGY
(2020)
Review
Oncology
Amnon A. Berger, Fanny Dao, Douglas A. Levine
Summary: Endometrial carcinoma is the most common gynecologic malignancy in the modern world, with limited therapeutic options. Researchers have been trying to identify prognostic and therapeutic biomarkers, with recent trials shedding new light on possible treatment strategies.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Harini Veeraraghavan, Herbert Alberto Vargas, Sanchez Alejandro-Jimenez, Maura Micco, Eralda Mema, Yulia Lakhman, Mireia Crispin-Ortuzar, Erich P. Huang, Douglas A. Levine, Rachel N. Grisham, Nadeem Abu-Rustum, Joseph O. Deasy, Alexandra Snyder, Martin L. Miller, James D. Brenton, Evis Sala
Article
Oncology
Kimberly K. Leslie, Virginia L. Filiaci, Adrianne R. Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley, Debra Richardson, David Mutch, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan E. McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Yovanni Casablanca, Amanda Jackson, Peter G. Rose, XunClare Zhou, Michael McHale, Heather Lankes, Douglas A. Levine, Carol Aghajanian
Summary: The study suggests that mutations in the TP53 gene are associated with improved progression-free survival (PFS) and overall survival (OS) in advanced endometrial cancer patients receiving bevacizumab, compared to temsirolimus. This indicates that TP53 mutational status may serve as a potential biomarker for guiding treatment choices in endometrial cancer patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Jessica N. McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stephanie Lam, Samuel Leung, Stefania Bellone, Adele Wong, Sara Y. Brucker, Cheng Han Lee, Blaise A. Clarke, David G. Huntsman, Marcus Q. Bernardini, Joanne Ngeow, Alessandro D. Santin, Paul Goodfellow, Douglas A. Levine, Martin Kobel, Stefan Kommoss, Tjalling Bosse, C. Blake Gilks, Aline Talhouk
Summary: Endometrial cancers with pathogenic POLE mutations are not associated with traditional risk parameters, and patients do not seem to benefit from adjuvant therapy. Low rates of recurrence/progression and high salvage rates may allow for safely decreasing treatment intensity for these patients.
Article
Oncology
Jessica N. McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stephanie Lam, Samuel Leung, Stefania Bellone, Adele Wong, Sara Y. Brucker, Cheng Han Lee, Blaise A. Clarke, David G. Huntsman, Marcus Q. Bernardini, Joanne Ngeow, Alessandro D. Santin, Paul Goodfellow, Douglas A. Levine, Martin Kobel, Stefan Kommoss, Tjalling Bosse, C. Blake Gilks, Aline Talhouk
Summary: Patients with ECs harboring pathogenic POLE mutations do not benefit from adjuvant therapy, as these mutations are not associated with most traditional risk parameters, and they exhibit low rates of adverse events with high and sustained salvage rates in cases of recurrence.
Article
Oncology
Shuang Zhang, Sonia Iyer, Hao Ran, Igor Dolgalev, Shengqing Gu, Wei Wei, Connor J. R. Foster, Cynthia A. Loomis, Narciso Olvera, Fanny Dao, Douglas A. Levine, Robert A. Weinberg, Benjamin G. Neel
Summary: Genetically informed, immunocompetent tumor models are crucial for evaluating conventional, targeted, and immune therapies. By engineering mouse fallopian tube organoids, researchers were able to study the effects of specific mutations found in high-grade serous tubo-ovarian cancer (HGSC) models, leading to the development of effective combination treatments for different genetic subgroups of HGSC. These findings highlight the importance of genotype-informed, syngeneic organoid models for understanding tumor biology and therapeutic responses.